Nirsevimab Biosimilar - Research Grade

Human

RSVï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

Respiratory syncytial virus (RSV) fusion protein is a principal target for antiviral and prophylaxis research. This recombinant human IgG1 kappa antibody, an unconjugated and non-therapeutic analog of nirsevimab, is generated in CHO cells against RSV. Released for research use only, it is purified to a low-endotoxin grade suited to in vivo applications and produced in scalable milligram (mg) to gram (g) batches for high-throughput and heavy-usage laboratories. It provides a consistent reference reagent for neutralization assays, viral-entry studies, functional characterization, and preclinical RSV models. Reliable batch-to-batch consistency suits laboratories running extended experimental campaigns.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.